SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-086059
Filing Date
2024-04-03
Accepted
2024-04-03 16:45:00
Documents
13
Period of Report
2024-04-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d819347d8k.htm   iXBRL 8-K 25874
  Complete submission text file 0001193125-24-086059.txt   148014

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA eigr-20240401.xsd EX-101.SCH 2852
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20240401_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20240401_pre.xml EX-101.PRE 11262
16 EXTRACTED XBRL INSTANCE DOCUMENT d819347d8k_htm.xml XML 3653
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 24819605
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)